scientific program • symposia - American Society for Reproductive ...

P-506 FOLLICLE STIMULATING HORMONE RECEPTOR
(FSHR) GENE POLYMORPHISM IN INFERTILE WOMEN (POOR
RESPONDER VS GOOD RESPONDER) UNDERGOING OVARIAN
STIMULATION COMPARED TO FERTILE WOMEN.
B. Sever, A. Karalok, T. Toptas, M. Simsek, O. Taskin, O. Alper. Akdeniz
University, Antalya, Turkey.
P-507 WHAT IS THE BEST COST-EFFECTIVE FSH DOSE FOR
INTRAUTERINE INSEMINATION?
G. M. Bedoschi, D. S. Zylbersztejn, R. Rosa Filho, M. B. Chehin, A. P.
Cedenho, R. Fraietta. Human Reproduction Seccion, Universidade
Federal de São Paulo, São Paulo, Brazil.
P-508 GONADOTROPHIN-RELEASING HORMONE AGONIST
AND ANTAGONIST: FACTORS DRIVING THE PREGANCY
OUTCOMES – AN EXPLORATORY ANALYSIS.
H. G. Al-Inany 1 , A. M. Abou-Setta 2 . 1 Obstetrics and Gynecology,
Cairo Universtiy, El-Manial, Cairo, Egypt; 2 Alberta Research Centre
for Health Evidence, University of Alberta, Edmonton, AB, Canada.
P-509 THE TYPE OF PROTOCOL USED FOR ART INDUCES
SIGNIFICANT DIFFERENCES IN EMBRYO DEVELOPMENTAL
KINETICS – A TIME-LAPSE STUDY.
M. Munoz, M. Cruz, P. Humaidan, N. Garrido, I. Perez-Cano, M.
Meseguer. IVI Alicante, Alicante, Spain; The Fertility Clinic, Odense,
Denmark.
P-510 IN PATIENTS WITH HIGH AMH LEVEL, IVF OUTCOME
BY GnRH AGONIST PROTOCOL IS HIGHER THAN ANTAGONIST
PROTOCOL.
J. H. Lee, Y. Y. Kim, E. M. Choi, S. G. Kim, K. H. Lee. Infertility Lab.,
Mamapapa&Baby OBGY, Ulsan, Republic of Korea.
P-511 CUMULUS CELLS GENE EXPRESSION PROFILE
FOLLOWING CONTROLLED OVARIAN STIMULATION WITH
HP-hMG OR rFSH IN A GnRH ANTAGONIST PROTOCOL: NEW
INDICATORS OF OVARIAN MICROENVIRONMENT HEALTH.
H. Dechaud 1,2,3 , S. Assou 1,3 , S. Moussaddykine 1,3 , E. Van den Abbeel 4 ,
H. Aasted 5 , S. Hamamah 1,2,3 . 1 CHU Montpellier, Institut de Recherche
en Biothérapie, Hôpital Saint-Eloi, Montpellier, Herault, France;
2 CHU Montpellier, Département de Biologie de la Reproduction,
Hôpital Arnaud de Villeneuve, Montpellier, Herault, France; 3 INSERM,
U1040, Montpellier, Herault, France; 4 Reproductive Medicine, UZ
Gent, Gent, Belgium; 5Global Clinical Research & Development
(Reproductive Medicine), Ferring Pharmaceuticals, Copenhagen,
Denmark.
P-512 GENOMIC EXPRESSION PROFILE COMPARISON FROM
CUMULUS CELLS DERIVING FROM HMG, rhFSH AND uhFSH.
D. Agudo, C. López, M. Alonso, E. Huguet, F. Bronet, A. Requena. IVI
Madrid, Madrid, Spain.
P-513 AMH TAILORED PROTOCOL IN IVF: SIMILAR
OUTCOMES CAN BE ACHIEVED REGARDLESS OF OVARIAN
RESERVE.
O. Rustamov1 , M. Krishnan2 , L. Turner2 , U. Shadyev3 , L. Nardo1 .
1Reproductive Medicine, St Mary’s Hospital, Central Manchester
University Hospital Foundation Trust, Manchester, Greater
Manchester, United Kingdom; 2School of Medicine, University of
Manchester, Manchester, Greater Manchester, United Kingdom;
3Medicine, Samarkand State Medical Institute, Samarkand,
Uzbekistan.
P-514 EXPLORING TWO DIFFERENT DOSES OF GnRH
AGONIST FOR THE INDUCTION OF FINAL OOCYTE
MATURATION IN GnRH ANTAGONIST-TREATED OOCYTE
DONOR CYCLES: A RETROSPECTIVE COMPARISON.
J. J. Guillén, M. Colodron, D. Bodri, C. Esteve, O. Coll, V. Vernaeve.
Clinica Eugin, Barcelona, Spain.
P-515 DO FEMALE TRANSLOCATION INFLUENCE THE
OVARIAN RESPONSE PATTERN TO CONTROLLED OVARIAN
STIMULATION IN PREIMPLANTATION GENETIC DIAGNOSIS?
C. Dechanet 1 , C. Castelli 2 , L. Reyftmann 1 , B. Hedon 1 , H. Dechaud 1 ,
T. Anahory 1 . 1 Service de Médecine de la Reproduction, CHU
POSTER PRESENTATIONS
166
Montpellier, Montpellier, France; 2 Departement de Biostatistique et
d’Épidémiologie, CHU Carremeau, Nimes, France.
__________________________________________________________
OVARIAN STIMULATION - HIGH RESPONDERS
P-516 ABSTRACT WITHDRAWN.
P-517 THE EFFECTS OF CABERGOLINE ON OVARIAN
HYPERSTIMULATION SYNDROME (OHSS) AND PREGNANCY
OUTCOMES ON IN VITRO FERTILIZATION (IVF) PATIENTS.
M. Gualtieri 1 , D. Hoffman 1 , M. Barrionuevo 1 , D. Christie 2 , Y.
Mouhayar 1 , S. J. Ory 2 . 1 Obstetrics and Gynecology, University
of Miami, Miller School of Medicine, Miami, FL; 2 Reproductive
Endocrinology and Infertility, Florida International University,
Margate, FL.
P-518 PREDICTION OF OVARIAN HYPERSTIMULATION
SYNDROME (OHSS) AND THE EFFECT OF LOW MOLECULAR
WEIGHT (LMWH) ON ITS PATHOGENESIS IN CONTROLLED
OVARIAN HYPERSTIMULATION: DOES IT HAVE A ROLE IN ITS
PREVENTION?
M. Elprince 1,2 , F. Wang 1,2 , Y. Zhu 2 , H. Huang 1,2,3 . 1 Reproductive
Endocrinology, Women’s Hospital, School of Medicine, Zhejiang
University, Hangzhou, Zhejiang, China; 2 Key Laboratory of Women’s
Reproductive Health of Zhejiang Province, Hangzhou, Zhejiang,
China; 3 Key Laboratory of Reproductive Genetics, Ministry of
Education of China, Hangzhou, Zhejiang, China.
P-519 GnRH-AGONIST (GnRH-A) TRIGGER IN GnRH-
ANTAGONIST CYCLES COMPARED TO HUMAN CHORIONIC
GONADOTROPIN (hCG) TRIGGER IN LONG LUTEAL
LEUPROLIDE DOWNREGULATION (LL) CYCLES FOR
HYPERRESPONDING OOCYTE DONORS.
R. L. Gustofson, E. S. Surrey, D. A. Minjarez, W. Schoolcraft. Colorado
Center for Reproductive Medicine, Lone Tree, CO.
P-520 GONADOTROPIN RELEASING AGONIST FOR
TRIGGERING FINAL OOCYTE MATURATION HAS FEWER SIDE
EFFECTS THAN RECOMBINANT hCG IN OOCYTE DONORS.
T. Singer, M. Costantini-Ferrando, J. Huang, I. Kligman, I. Cholst.
The Center for Reproductive Medicine and Infertility, Weill Cornell
Medical College, New York, NY.
P-521 THE LUTEINIZING HORMONE RESPONSE TO A
LEUPROLIDE ACETATE “TRIGGER” IN IN VITRO FERTILIZATION
CONSISTENTLY ACHIEVES ACCEPTABLE RETRIEVAL EFFICIENCY,
OOCYTE NUCLEAR MATURATION, AND FERTILIZATION RATES.
M. P. Provost 1 , K. O. Pomeroy 2 , R. D. Gerkin 3 , D. V. Moffitt 2 .
1 Department of Obstetrics & Gynecology, Banner Good Samaritan
Medical Center, Phoenix, AZ; 2 Arizona Reproductive Medical
Specialists, Phoenix, AZ; 3 Banner Health Research Administration,
Banner Good Samaritan Medical Center, Phoenix, AZ.
__________________________________________________________
OVARIAN STIMULATION - POOR RESPONDERS
P-522 GONADOTROPHIN-RELEASING HORMONE
ANTAGONISTS FOR ASSISTED REPRODUCTIVE TECHNOLOGY
IN WOMEN WITH POOR OVARIAN RESPONSE. SUBGROUP
ANALYSIS OF COCHRANE SYSTEMATIC REVIEW AND META-
ANALYSIS.
M. Youssef1 , H. Al-Inany2 , M. Aboulghar3 , A. Abou-Setta4 .
1Egyptian International Fertility IVF Center (EIFC-IVF), Cairo, Egypt;
2Department of Obstetrics & Gynaecology, Faculty of Medicine,
Cairo University, Cairo, Egypt; 3Egyptian IVF-ET Center, Cairo, Egypt;
4University of Alberta Evidence-based Practice Centre (UA-EPC),
Alberta Research Centre for Health Evidence (ARCHE), Edmonton,
AB, Canada.